2024
How I treat challenging transfusion cases in sickle cell disease
Chou S, Hendrickson J. How I treat challenging transfusion cases in sickle cell disease. Blood 2024 PMID: 38728382, DOI: 10.1182/blood.2023023648.Peer-Reviewed Original ResearchDelayed hemolytic transfusion reactionSickle cell diseaseRed blood cellsTransfusion of red blood cellsRed blood cell alloantibodiesRed blood cell transfusionCell diseaseHemolytic transfusion reactionsManagement of complicationsAlloimmunized patientsRh alloimmunizationCurative therapyTransfusion guidelinesTransfusion recipientsClinical dilemmaFuture transfusionsTransfusionPatient populationTransfusion casesTransfusion reactionsBlood donorsRH variantsBlood cellsAlloimmunizationMedicine providersDecreasing alloimmunization‐specific mortality in sickle cell disease in the United States: Cost‐effectiveness of a shared transfusion resource
Ito S, Pandya A, Hauser R, Krishnamurti L, Stites E, Tormey C, Krumholz H, Hendrickson J, Goshua G. Decreasing alloimmunization‐specific mortality in sickle cell disease in the United States: Cost‐effectiveness of a shared transfusion resource. American Journal Of Hematology 2024, 99: 570-576. PMID: 38279581, DOI: 10.1002/ajh.27211.Peer-Reviewed Original ResearchSickle cell diseaseDelayed hemolytic transfusion reactionQuality-adjusted life expectancyAlloimmunized patientsPatient populationRed blood cell alloimmunizationCell diseaseCost-effective interventionMedical expenditure of patientsHealth system perspectiveExpenditure of patientsIncremental cost-effectiveness ratioHemolytic transfusion reactionsUnited StatesMarkov cohort simulationCost-effectiveAverage patient populationCost-effectiveness ratioBirth cohortAnalytical time horizonAntibody historyCohort simulationTransfusionTransfusion reactionsLife expectancy
2023
Associations between ABO non‐identical platelet transfusions and patient outcomes—A multicenter retrospective analysis
Bougie D, Reese S, Birch R, Bookwalter D, Mitchell P, Roh D, Kreuziger L, Cable R, Goel R, Gottschall J, Hauser R, Hendrickson J, Hod E, Josephson C, Kahn S, Kleinman S, Mast A, Ness P, Roubinian N, Sloan S, Study‐IV‐Pediatric F. Associations between ABO non‐identical platelet transfusions and patient outcomes—A multicenter retrospective analysis. Transfusion 2023, 63: 960-972. PMID: 36994786, PMCID: PMC10175171, DOI: 10.1111/trf.17319.Peer-Reviewed Original ResearchConceptsPlatelet transfusionsHazard ratioPatient outcomesMulticenter retrospective analysisPlatelet transfusion requirementsGroup O recipientsRecipient's blood groupRisk of mortalitySpecific patient populationsBlood group ARecipient EpidemiologyTransfusion requirementsB recipientsOverall cohortProspective studyO recipientsPatient populationRetrospective analysisPlatelet dosesGroup ATransfusionABO antigensABO groupPatient exposureSignificant association
2019
Recipient factors influencing red blood cell alloimmunization
Hendrickson J. Recipient factors influencing red blood cell alloimmunization. ISBT Science Series 2019, 15: 194-200. DOI: 10.1111/voxs.12485.Peer-Reviewed Original ResearchSickle cell diseaseRBC alloantibodiesMyelodysplastic syndromeRed blood cell alloimmunizationRed blood cell alloantibodiesRBC alloantibody formationReductionist murine modelHaemolytic transfusion reactionsType of inflammationHigh prevalence ratesForms of autoimmunityDetectable alloantibodiesRBC alloimmunizationTransfusion avoidanceTransfusion burdenAlloantibody formationAntigen matchingRecipient factorsAntibody screenPatient populationHaemolytic diseaseRBC exposureRisk factorsTransfusion reactionsMurine model
2018
6 A Novel Association Between High Red Blood Cell Alloimmunization Rates and Hereditary Hemorrhagic Telangiectasia (HHT)
Zheng Y, Pollak J, Henderson K, Hendrickson J, Tormey C. 6 A Novel Association Between High Red Blood Cell Alloimmunization Rates and Hereditary Hemorrhagic Telangiectasia (HHT). American Journal Of Clinical Pathology 2018, 149: s166-s166. DOI: 10.1093/ajcp/aqx149.375.Peer-Reviewed Original ResearchHereditary hemorrhagic telangiectasiaAlloimmunization rateRBC transfusionHHT patientsHemorrhagic telangiectasiaRed blood cell transfusionFirst RBC transfusionMore RBC transfusionsNon-ABO alloantibodiesProphylactic antigen matchingRBC alloimmunization rateBlood cell transfusionMultiple arteriovenous malformationsStudent's t-testAutosomal dominant disorderCommon alloantibodiesHHT subjectsCell transfusionReferral centerControl patientsMale patientsAntigen matchingRetrospective studyAntibody screenPatient population
2007
An Intact Spleen Is Required for Alloimmunization to Transfused Red Blood Cells Due to Intrasplenic Activation of CD4+ T Cells.
Hendrickson J, Roback J, Hillyer C, Zimring J. An Intact Spleen Is Required for Alloimmunization to Transfused Red Blood Cells Due to Intrasplenic Activation of CD4+ T Cells. Blood 2007, 110: 453. DOI: 10.1182/blood.v110.11.453.453.Peer-Reviewed Original ResearchNon-splenectomized miceRBC alloimmunizationT cellsSplenectomized miceDivision of CD4Adoptive transferRed blood cellsPrecursor frequencyHelper T-cell precursor frequencyT cell precursor frequencyHelper T cell functionHelper T cell responsesBlood cellsHuman dose equivalentRate of alloimmunizationAntigen-specific CD4T cell responsesIgG-specific ELISACell precursor frequencyT cell functionDetectable alloantibodiesPatient populationIntact spleenLymphatic preparationsMurine model
2006
Lack of Alloantibody Response to Red Blood Cell Antigens in Juvenile Mice Following Transfusion: Non-Immunogenic or Tolerogenic Response?.
Hendrickson J, Josephson C, Chadwick T, Zimring J. Lack of Alloantibody Response to Red Blood Cell Antigens in Juvenile Mice Following Transfusion: Non-Immunogenic or Tolerogenic Response?. Blood 2006, 108: 955. DOI: 10.1182/blood.v108.11.955.955.Peer-Reviewed Original ResearchRed blood cellsAlloantibody responsesJuvenile miceAdult miceRBC antigensPotential clinical implicationsRBC alloimmunizationClinical implicationsWeight-adjusted volumeRed blood cell antigensEffects of inflammationBlood cell antigensMonths of ageOngoing studiesViral inflammationTolerogenic responsesIgG levelsPediatric populationTransfusion recipientsImmunogenic stimulusPatient populationNeonatal humansTolerogenic stimulusMurine modelAlloimmunization